tetano
Editor, Senior Moderator
World J Virol
. 2024 Mar 25;13(1):91149.
doi: 10.5501/wjv.v13.i1.91149. Impact of metabolic dysfunction-associated steatotic liver disease on COVID-19 hospitalizations: A propensity-matched analysis of the United States
Abdullah Sohail[SUP] 1 [/SUP], Hassam Ali[SUP] 2 [/SUP], Pratik Patel[SUP] 3 [/SUP], Subanandhini Subramanium[SUP] 4 [/SUP], Dushyant Singh Dahiya[SUP] 5 [/SUP], Amir H Sohail[SUP] 6 [/SUP], Manesh Kumar Gangwani[SUP] 7 [/SUP], Sanjaya K Satapathy[SUP] 8 [/SUP]
Affiliations
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD), formally known as nonalcoholic fatty liver disease, is the most common chronic liver disease in the United States. Patients with MASLD have been reported to be at a higher risk of developing severe coronavirus disease 2019 (COVID-19) and death. However, most studies are single-center studies, and nationwide data in the United States is lacking.
Aim: To study the influence of MASLD on COVID-19 hospitalizations during the initial phase of the pandemic.
Methods: We retrospectively analyzed the 2020 National Inpatient Sample (NIS) database to identify primary COVID-19 hospitalizations based on an underlying diagnosis of MASLD. A matched comparison cohort of COVID-19 hospitalizations without MASLD was identified from NIS after 1: N propensity score matching based on gender, race, and comorbidities, including hypertension, heart failure, diabetes, and cirrhosis. The primary outcomes included inpatient mortality, length of stay, and hospitalization costs. Secondary outcomes included the prevalence of systemic complications.
Results: A total of 2210 hospitalizations with MASLD were matched to 2210 hospitalizations without MASLD, with a good comorbidity balance. Overall, there was a higher prevalence of severe disease with more intensive care unit admissions (9.5% vs 7.2%, P = 0.007), mechanical ventilation (7.2% vs 5.7%, P = 0.03), and septic shock (5.2% vs 2.7%, P <0.001) in the MASLD cohort than in the non-MASLD cohort. However, there was no difference in mortality (8.6% vs 10%, P = 0.49), length of stay (5 d vs 5 d, P = 0.25), and hospitalization costs (42081.5 $ vs 38614$, P = 0.15) between the MASLD and non-MASLD cohorts.
Conclusion: The presence of MAFLD with or without liver cirrhosis was not associated with increased mortality in COVID-19 hospitalizations; however, there was an increased incidence of severe COVID-19 infection. This data (2020) predates the availability of COVID-19 vaccines, and many MASLD patients have since been vaccinated. It will be interesting to see if these trends are present in the subsequent years of the pandemic.
Keywords: COVID-19; Hospital charges; Inpatient resource utilization; Metabolic dysfunction-associated steatotic liver disease; Prevalence.
. 2024 Mar 25;13(1):91149.
doi: 10.5501/wjv.v13.i1.91149. Impact of metabolic dysfunction-associated steatotic liver disease on COVID-19 hospitalizations: A propensity-matched analysis of the United States
Abdullah Sohail[SUP] 1 [/SUP], Hassam Ali[SUP] 2 [/SUP], Pratik Patel[SUP] 3 [/SUP], Subanandhini Subramanium[SUP] 4 [/SUP], Dushyant Singh Dahiya[SUP] 5 [/SUP], Amir H Sohail[SUP] 6 [/SUP], Manesh Kumar Gangwani[SUP] 7 [/SUP], Sanjaya K Satapathy[SUP] 8 [/SUP]
Affiliations
- PMID: 38616849
- PMCID: PMC11008396
- DOI: 10.5501/wjv.v13.i1.91149
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD), formally known as nonalcoholic fatty liver disease, is the most common chronic liver disease in the United States. Patients with MASLD have been reported to be at a higher risk of developing severe coronavirus disease 2019 (COVID-19) and death. However, most studies are single-center studies, and nationwide data in the United States is lacking.
Aim: To study the influence of MASLD on COVID-19 hospitalizations during the initial phase of the pandemic.
Methods: We retrospectively analyzed the 2020 National Inpatient Sample (NIS) database to identify primary COVID-19 hospitalizations based on an underlying diagnosis of MASLD. A matched comparison cohort of COVID-19 hospitalizations without MASLD was identified from NIS after 1: N propensity score matching based on gender, race, and comorbidities, including hypertension, heart failure, diabetes, and cirrhosis. The primary outcomes included inpatient mortality, length of stay, and hospitalization costs. Secondary outcomes included the prevalence of systemic complications.
Results: A total of 2210 hospitalizations with MASLD were matched to 2210 hospitalizations without MASLD, with a good comorbidity balance. Overall, there was a higher prevalence of severe disease with more intensive care unit admissions (9.5% vs 7.2%, P = 0.007), mechanical ventilation (7.2% vs 5.7%, P = 0.03), and septic shock (5.2% vs 2.7%, P <0.001) in the MASLD cohort than in the non-MASLD cohort. However, there was no difference in mortality (8.6% vs 10%, P = 0.49), length of stay (5 d vs 5 d, P = 0.25), and hospitalization costs (42081.5 $ vs 38614$, P = 0.15) between the MASLD and non-MASLD cohorts.
Conclusion: The presence of MAFLD with or without liver cirrhosis was not associated with increased mortality in COVID-19 hospitalizations; however, there was an increased incidence of severe COVID-19 infection. This data (2020) predates the availability of COVID-19 vaccines, and many MASLD patients have since been vaccinated. It will be interesting to see if these trends are present in the subsequent years of the pandemic.
Keywords: COVID-19; Hospital charges; Inpatient resource utilization; Metabolic dysfunction-associated steatotic liver disease; Prevalence.